Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth (CGC) will release its second-quarter fiscal 2027 financial results before markets open on November 6, 2026.
The quarter ended September 30, 2026. CEO Luc Mongeau and CFO Tom Stewart will host an audio webcast at 10:00 AM ET that day. A replay will remain available until 11:59 PM ET on February 4, 2027.
Canopy Growth (CGC) received European Union Good Manufacturing Practice certification for manufacturing and packaging activities at its Smiths Falls, Ontario facility.
The certification, issued by Germany’s Tübingen Regional Council, covers softgel manufacturing and primary packaging of softgels, oral liquids and dried cannabis flower. It expands certified capabilities within the company’s supply chain linking Canadian production with European distribution. Supply to European markets remains subject to applicable product and market requirements. Canopy Growth is focused on accelerating commercial execution in Germany, Poland and the UK, deepening healthcare relationships and expanding patient product choices.
Canopy Growth (CGC) appointed Sebastian Blöte country manager for Germany, effective October 1, 2026.
He will lead the company’s commercial strategy in Germany, including sales and relationships with partners and healthcare professionals. Canopy Growth reported double-digit sequential growth in its international medical cannabis business for the past three quarters and has enhanced its European Union Good Manufacturing Practice supply capabilities from Canadian cultivation.
Canopy Growth (CGC) adjourned its September 25, 2026, shareholder meeting because the required quorum was not present. The meeting will reconvene by live audio webcast on October 23 at 1:00 p.m. ET. Shareholders have until 9:00 a.m. ET that day to submit proxy votes. Quorum requires the participation of 33 1/3% of outstanding shares entitled to vote.
Canopy Growth (CGC) has extended the proxy voting deadline for its 2026 Annual General and Special Meeting to 12:00 p.m. ET on Friday, September 25, 2026.
The Meeting will be held the same day at 1:00 p.m. ET as a live audio webcast at www.virtualshareholdermeeting.com/WEED2026. The extension is intended to give shareholders more time to vote and to help the company reach the required quorum of 33 1/3% of outstanding common shares entitled to vote, as required by Nasdaq listing rules and the company’s by-laws.
Canopy Growth (CGC) will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom under its Spectrum Therapeutics brand.
The products will be supplied to GROW Group U.K. Ltd., which will commercialize them in the UK medical cannabis market. This initial launch marks the first introduction of Canopy Growth’s portfolio products into the UK and follows renewal of EU Good Manufacturing Practice certification at the company’s Kincardine, Ontario cultivation facility, supporting its broader European medical cannabis strategy.
Canopy Growth (CGC) is reminding shareholders to vote ahead of its Annual General and Special Meeting on September 25, 2026, at 1:00 p.m. ET.
Votes must be submitted by 1:00 p.m. ET on September 23, 2026, to be counted. Shareholders of record on July 31, 2026, may vote. Nasdaq rules require a 33 1/3% quorum. The board recommends voting FOR Items 1–6 and EVERY ONE year on Item 7.
Canopy Growth (CGC) announced an expansion of its medical cannabis portfolio in Australia, adding new product formats and formulations across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands.
The company introduced its first pastille and all-in-one vape formats in the market, alongside new oil products that include CBG and CBN and additional softgel options beyond isolate-based formulations. Two new flower SKUs were also added under the Twd. value range, which the company said responds to Australian prescribers’ and patients’ requests for more choice in formats and formulations.
Canopy Growth (Nasdaq: CGC) has mailed or provided online access to proxy materials and its fiscal 2026 annual report for the Annual General and Special Meeting on September 25, 2026 at 1:00 PM ET, to be held via live audio webcast at www.virtualshareholdermeeting.com/WEED2026.
Shareholders of record as of July 31, 2026 are eligible to vote and are urged to do so by 1:00 PM ET on September 23, 2026 to ensure their votes are counted and help meet Nasdaq’s 33 1/3% quorum requirement. Items up for vote include election of directors, appointment of MNP LLP as auditor, a discretionary share consolidation proposal, an advance notice by-law, omnibus incentive plan entitlements, and advisory votes on executive compensation and its frequency.
Canopy Growth (Nasdaq: CGC; TSX: WEED) announced that its Kincardine, Ontario cultivation facility has secured renewed EU Good Manufacturing Practice (EU GMP) certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg.
The renewed status allows Canopy Growth to continue supplying Canadian-grown medical cannabis flower from Kincardine to European markets. Kincardine serves as the anchor asset in the Company’s end-to-end EU GMP flower supply chain, linked to its second EU GMP facility in Sankt Leon-Rot, Germany. According to Canopy Growth, growing business momentum in Europe contributed to a 10% year-over-year increase in international cannabis net revenue in the first quarter of fiscal 2027.